|
1
|
Hahne M, Kataoka T, Schröter M, Hofmann K,
Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE,
et al: APRIL, a new ligand of the tumor necrosis factor family,
stimulates tumor cell growth. J Exp Med. 188:1185–1190. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kimberley FC, van Bostelen L, Cameron K,
Hardenberg G, Marquart JA, Hahne M and Medema JP: The proteoglycan
(heparan sulfate proteoglycan) binding domain of APRIL serves as a
platform for ligand multimerization and cross-linking. FASEB J.
23:1584–1595. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deshayes F, Laprée G, Portier A, Richard
Y, Pencalet P, Mahieu-Caputo D, Horellou P and Tsapis A: Abnormal
production of the TNF-homologue APRIL increases the proliferation
of human malignant glioblastoma cell lines via a specific receptor.
Oncogene. 23:3005–3012. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun B, Wang H, Wang X, Huang H, Ding W,
Jing R, Shi G and Zhu L: A proliferation-inducing ligand: a new
biomarker for non-small cell lung cancer. Exp Lung Res. 35:486–500.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mhawech-Fauceglia P, Kaya G, Sauter G,
McKee T, Donze O, Schwaller J and Huard B: The source of APRIL
up-regulation in human solid tumor lesions. J Leukoc Biol.
80:697–704. 2006.PubMed/NCBI
|
|
6
|
Planelles L, Medema JP, Hahne M and
Hardenberg G: The expanding role of APRIL in cancer and immunity.
Curr Mol Med. 8:829–844. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang F, Chen L, Mao ZB, Shao JG, Tan C and
Huang WD: Lentivirus-mediated short hairpin RNA targeting the APRIL
gene suppresses the growth of pancreatic cancer cells in
vitro and in vivo. Oncol Rep. 20:135–139.
2008.PubMed/NCBI
|
|
8
|
Moreaux J, Veyrune JL, De Vos J and Klein
B: APRIL is overexpressed in cancer: link with tumor progression.
BMC Cancer. 9:832009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dillon SR, Gross JA, Ansell SM and Novak
AJ: An APRIL to remember: novel TNF ligands as therapeutic targets.
Nat Rev Drug Discov. 5:235–246. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature.
391:806–811. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cogoni C and Macino G:
Post-transcriptional gene silencing across kingdoms. Curr Opin
Genet Dev. 10:638–643. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sioud M: Therapeutic siRNAs. Trends
Pharmacol Sci. 25:22–28. 2004. View Article : Google Scholar
|
|
13
|
Wang S, Shi Z, Liu W, Jules J and Feng X:
Development and validation of vectors containing multiple siRNA
expression cassettes for maximizing the efficiency of gene
silencing. BMC Biotechnol. 6:502006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding W, Wang J, Sun B, Ju S, Yuan H, Wang
X, Wang Y and Wang H: APRIL knockdown suppresses migration and
invasion of human colon carcinoma cells. Clin Biochem.
42:1694–1698. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hendriks J, Planelles L, de Jong-Odding J,
Hardenberg G, Pals ST, Hahne M, Spaargaren M and Medema JP: Heparan
sulfate proteoglycan binding promotes APRIL-induced tumor cell
proliferation. Cell Death Differ. 12:637–648. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rennert P, Schneider P, Cachero TG,
Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C,
Strauch K, Browning JL, Ambrose C and Tschopp J: A soluble form of
B cell maturation antigen, a receptor for the tumor necrosis factor
family member APRIL, inhibits tumor cell growth. J Exp Med.
192:1677–1684. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marsters SA, Yan M, Pitti RM, Haas PE,
Dixit VM and Ashkenazi A: Interaction of the TNF homologues BLyS
and APRIL with the TNF receptor homologues BCMA and TACI. Curr
Biol. 10:785–788. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu Y, Bressette D, Carrell JA, Kaufman T,
Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, et al: Tumor
necrosis factor (TNF) receptor superfamily member TACI is a high
affinity receptor for TNF family members APRIL and BLyS. J Biol
Chem. 275:35478–35485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esko JD and Lindahl U: Molecular diversity
of heparan sulfate. J Clin Invest. 108:169–173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gallagher JT: Heparan sulfate: growth
control with a restricted sequence menu. J Clin Invest.
108:357–361. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Perrimon N and Bernfield M: Specificities
of heparan sulphate proteoglycans in developmental processes.
Nature. 404:725–728. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayashida K, Johnston DR, Goldberger O and
Park PW: Syndecan-1 expression in epithelial cells is induced by
transforming growth factor beta through a PKA-dependent pathway. J
Biol Chem. 281:24365–24374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ding W, Ju S, Jiang S, Zhu L, Wang Y and
Wang H: Reduced APRIL expression induces cellular senescence via a
HSPG-dependent pathway. Pathol Oncol Res. 15:693–701. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dykxhoorn DM: RNA interference as an
anticancer therapy: a patent perspective. Expert Opin Ther Pat.
19:475–491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang SL, Yao HH and Qin ZH: Strategies for
short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol
Ther. 9:1357–1368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gou D, Weng T, Wang Y, Wang Z, Zhang H,
Gao L, Chen Z, Wang P and Liu L: A novel approach for the
construction of multiple shRNA expression vectors. J Gene Med.
9:751–763. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan Y, Zhang J, Guo JL, Huang W and Yang
YZ: Multiple shRNA-mediated knockdown of TACE reduces the
malignancy of HeLa cells. Cell Biol Int. 33:158–164. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
30
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ortega J, Vigil CE and Chodkiewicz C:
Current progress in targeted therapy for colorectal cancer. Cancer
Control. 17:7–15. 2010.PubMed/NCBI
|
|
32
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jazag A, Kanai F, Ijichi H, Tateishi K,
Ikenoue T, Tanaka Y, Ohta M, Imamura J, Guleng B, Asaoka Y, et al:
Single small-interfering RNA expression vector for silencing
multiple transforming growth factor-beta pathway components.
Nucleic Acids Res. 33:e1312005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
ter Brake O, Konstantinova P, Ceylan M and
Berkhout B: Silencing of HIV-1 with RNA interference: a multiple
shRNA approach. Mol Ther. 14:883–892. 2006.PubMed/NCBI
|
|
35
|
Song J, Giang A, Lu Y, Pang S and Chiu R:
Multiple shRNA expressing vector enhances efficiency of gene
silencing. BMB Rep. 41:358–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
